Suscribirse

What do patients consider when making decisions about treatment for hepatitis C? - 21/08/11

Doi : 10.1016/j.amjmed.2005.05.029 
Liana Fraenkel, MD, MPH a, b, , Sarah McGraw, PhD c, Suchat Wongcharatrawee, MD a, b, d, Guadalupe Garcia-Tsao, MD a, b, d
a Department of Medicine, VA Connecticut Healthcare System, West Haven, Conn 
b Department of Medicine, Yale University School of Medicine, New Haven, Conn 
c New England Research Institutes, Watertown, Mass 
d Hepatitis C Resource Center, VA Connecticut Healthcare System, New Haven, Conn. 

Requests for reprints should be addressed to Liana Fraenkel, MD, MPH, Yale University School of Medicine, Section of Rheumatology, 300 Cedar St, TAC#525, PO Box 208031, New Haven, CT 06520-8031

Abstract

Purpose

There are few data describing decision-making in chronic hepatitis C infection from the patient’s perspective. In this study, we sought to investigate the factors that influence patients’ decisions as they consider treatment for hepatitis C infection.

Subjects

Consecutive patients attending outpatient liver clinics were recruited. Purposeful sampling was employed to include patients who were currently being treated or had recently been treated for chronic hepatitis C infection with pegylated-interferon and ribavirin as well as patients who had refused therapy.

Methods

We conducted focus groups until thematic saturation was reached. All focus groups were facilitated by the same PhD-level senior research scientist, and constant comparative methods were used to analyze the data.

Results

A total of 40 patients (80% male) participated in 8 focus groups. The factors influencing patients’ decision-making that emerged most frequently during the focus groups were consideration of risk benefit tradeoffs, protected values, heuristics, participants’ conceptualization of hepatitis C infection, social issues, and physicians’ recommendations.

Conclusion

Ideally, complex decision-making is based on careful consideration of the tradeoffs related to available options. Our findings suggest that patients’ treatment decisions are influenced by multiple factors besides the risks and benefits of interferon and ribavirin. By being aware of these factors physicians can improve decision-making in hepatitis C infection by 1) determining whether patients’ decisions are biased by heuristics or protect values, 2) understanding how patients’ conceptualization of their illness influences their attitudes toward therapy, and by 3) ensuring that patients understand that social responsibilities need not necessarily preclude treatment because therapy can be discontinued if adverse effects become intolerable.

El texto completo de este artículo está disponible en PDF.

Keywords : Hepatitis C, Decision-making, Pegylated-interferon, Ribavirin


Esquema


 This study was funded by the VA Health Services Research Department and the Yale Liver Center Pilot Project Grant DK P3034989. Dr. Fraenkel is also supported by the K23 Award AR048826-01 A1.


© 2005  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 118 - N° 12

P. 1387-1391 - décembre 2005 Regresar al número
Artículo precedente Artículo precedente
  • Pacemaker stress echocardiography predicts cardiac events in patients with permanent pacemaker
  • Elena Biagini, Arend F.L. Schinkel, Abdou Elhendy, Jeroen J. Bax, Vittoria Rizzello, Ron T. van Domburg, Boudewijn J. Krenning, Olaf Schouten, Angelo Branzi, Guido Rocchi, Maarten L. Simoons, Don Poldermans
| Artículo siguiente Artículo siguiente
  • Quality of care in for-profit and not-for-profit health plans enrolling Medicare beneficiaries
  • Eric C. Schneider, Alan M. Zaslavsky, Arnold M. Epstein

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.